The next phase of automation is not a distant prospect but a live restructuring of how products are made, buildings are ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) ...

Unlike traditional GLP-1 therapies, which often cause muscle loss alongside fat reduction, WVE-007 achieved a 9.4% reduction in visceral fat and a 4.5% reduction in total body fat while simultaneously ...

Wave Life Sciences (WVE) announced positive results from its phase 1b/2a RestorAAtion-2 study using WVE-006 for the treatment of patients with alpha-1 antitrypsin deficiency [AATD]. It was shown that ...

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...

BOCA RATON, Fla., Oct. 31, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.